L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
The main purpose of this study is to evaluate the safety and effectiveness of liquid tumor infiltrating lymphocytes (L-TIL) combined with tislelizumab as the first-line treatment in patients with advanced malignant melanoma. This study plan to include stage III or IV unresectable or metastatic cutaneous or acral malignant melanoma patients, treat with L-TIL 4 cycles with each infusion (3 -10) x10\*9/m2 cells, combined with tislelizumab 200mg, iv, Q3W. It is expected that 30 patients will be enrolled in this study.
Malignant Melanoma
DRUG: Tislelizumab
Efficacy (ORR), The objective response rate (ORR) at 8 weeks from baseline., 8 weeks|Efficacy (ORR), The objective response rate (ORR) at 16 weeks., 16 weeks|Efficacy (DOR), The duration of response (DOR) at 1-year., 1 year|Efficacy (DOR), The duration of response (DOR) at 2-year., 2 years
Progression free survival (PFS), The PFS rate at 1 year., 1 year|Progression free survival (PFS), The PFS rate at 2-year., 2 years|Overall survival (OS), The OS rate at 1 year., 1 year|Overall survival (OS), The OS rate at 2-year., 2 years|Safety (adverse events), The adverse events followed by treatment., 2 years
The main purpose of this study is to evaluate the safety and effectiveness of liquid tumor infiltrating lymphocytes (L-TIL) combined with tislelizumab as the first-line treatment in patients with advanced malignant melanoma. This study plan to include stage III or IV unresectable or metastatic cutaneous or acral malignant melanoma patients, treat with L-TIL 4 cycles with each infusion (3 -10) x10\*9/m2 cells, combined with tislelizumab 200mg, iv, Q3W. It is expected that 30 patients will be enrolled in this study.